Carlsmed, Inc.

Name: Carlsmed, Inc. standardized financial statements, quarterly
Creator: Listed

CARLNasdaqCIK 1794546HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$18.9m, Q2 FY2026

Operating income−$11.0m, Q2 FY2026

Net income−$10.5m, Q2 FY2026

Carlsmed, Inc., income statement, quarterly
Line item	Unit	period not labelled2024-03-31	period not labelled2024-06-30	period not labelled2024-09-30	period not labelled2024-12-31	period not labelled2025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	not reported	6.1	6.6	9.4	10.2	12.1	13.1	15.2	16.1	18.9
Cost of revenue	$m	not reported	1.5	1.8	2.4	2.6	3.2	3.1	3.6	3.7	4.4
Gross profit	$m	not reported	4.6	4.8	7.0	7.6	8.9	9.9	11.6	12.4	14.5
Research and development	$m	not reported	4.0	4.0	3.0	3.2	4.2	4.4	5.3	5.2	6.0
Operating income	$m	not reported	(6.3)	(7.8)	(4.7)	(5.7)	(6.5)	(9.0)	(9.3)	(9.3)	(11.0)
Interest expense	$m	not reported	0.3	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3
Income tax	$m	not reported	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(5.4)	(6.3)	(7.8)	(4.7)	(5.7)	(6.8)	(8.5)	(8.6)	(8.7)	(10.5)
Diluted EPS	$ per share	not reported	(1.55)	(2.06)	not reported	(1.47)	(1.47)	(0.40)	not reported	(0.32)	(0.39)
Basic EPS	$ per share	not reported	(1.55)	(2.06)	not reported	(1.47)	(1.47)	(0.40)	not reported	(0.32)	(0.39)

Balance sheet

Cash and equivalents$46.2m, Q2 FY2026

Long-term debt$15.4m, Q2 FY2026

Shareholders' equity$84.2m, Q2 FY2026

Carlsmed, Inc., balance sheet, quarterly
Line item	Unit	period not labelled2023-12-31	period not labelled2024-03-31	period not labelled2024-06-30	period not labelled2024-09-30	period not labelled2024-12-31	period not labelled2025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	7.2	not reported	38.1	44.4	40.1	43.4	33.5	115	85.8	73.0	46.2
Current assets	$m	not reported	not reported	not reported	not reported	49.4	not reported	46.2	131	127	115	110
Total assets	$m	not reported	not reported	not reported	not reported	51.8	not reported	53.3	135	130	119	118
Current liabilities	$m	not reported	not reported	not reported	not reported	8.8	not reported	9.5	10.9	14.3	9.7	12.4
Total liabilities	$m	not reported	not reported	not reported	not reported	26.2	not reported	27.6	28.2	31.3	26.5	34.0
Long-term debt	$m	not reported	not reported	not reported	not reported	15.4	not reported	15.4	15.4	15.3	15.4	15.4
Shareholders' equity	$m	(46.1)	(51.5)	(57.7)	(66.0)	(70.6)	(76.6)	(83.1)	107	98.9	92.2	84.2

Cash flow

Operating cash flow−$7.4m, Q2 FY2026

Capital expenditure$121.0k, Q2 FY2026

Carlsmed, Inc., cash flow, quarterly
Line item	Unit	period not labelled2024-09-30	period not labelled2024-12-31	period not labelled2025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(7.6)	(4.2)	(8.2)	(7.0)	(8.5)	(5.3)	(13.0)	(7.4)
Capital expenditure	$m	0.1	0.1	0.1	0.3	0.2	0.1	0.1	0.1

Diluted shares (weighted)27.19m, Q2 FY2026

Carlsmed, Inc., shares, quarterly
Line item	Unit	period not labelled2024-06-30	period not labelled2024-09-30	period not labelled2025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	4.1	4.1	4.3	4.6	21.1	26.8	27.2

Shares outstanding: 27.30m at Aug 3, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.